Arcus Biosciences (RCUS) Tops Q1 EPS by 95c

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($0.05), $0.95 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $145 million versus the consensus estimate of $30.88 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Worthington Enterprises raises dividend 5%, adds board member
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'